Source: Annual Congress 2009 - COPD: basic science and clinical studies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Andelid, P. Glader, B. Balder, A. Ekberg-Jansson, A. Lindén (Göteborg, Sweden). Myeloperoxidase increased in plasma in patients with stable COPD. Eur Respir J 2009; 34: Suppl. 53, 916

Member's Comments

No comment yet.

Related content which might interest you: Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009 Pulmonary rehabilitation causes a decrease in interleukin-8 and myeloperoxidase levels in sputum of patients with COPD Source: Annual Congress 2009 - Mechanisms of lung injury: COPD, asthma and acute lung injury Year: 2009 Decreased levels of myeloperoxidase in induced sputum of COPD patients after oral glucocorticoids treatment Source: Eur Respir J 2002; 20: Suppl. 38, 404s Year: 2002 Magnesium levels in erythrocytes and plasma in patients with exacerbated COPD Source: Eur Respir J 2001; 18: Suppl. 33, 429s Year: 2001 Increased levels of hyaluronan in induced sputum from COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 436s Year: 2003 Elevated circulating MMP-9 is associated with increased exacerbation risk in COPD: results from SPIROMICS and COPDGene Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 MMP-9 expression and activity is incresed in the BAL of patients with acute exacerbation of COPD Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Alterations in sputum inflammatory markers during exacerbations for COPD patients with different stable state levels Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019 Overexpression of chitotriosidase and YKL-40 in serum and sputum in healthy smokers and patients with  chronic obstructive pulmonary disease Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 Plasma levels of soluble RAGE are lower in COPD Source: Annual Congress 2009 - COPD and asthma - from the cell to the clinic Year: 2009 Il-6 levels in sera and induced sputum of COPD patients during exacerbations and stable period Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Neutrophil activity assessed using a novel serological marker of human neutrophil elastase degraded calprotectin is elevated in patients with COPD or IPF Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery Year: 2021 Increased levels of osteopontin in sputum supernatant in patients with COPD Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers Year: 2012 Plasma leakage is elevated in COPD airways Source: Eur Respir J 2005; 26: Suppl. 49, 441s Year: 2005 Plasma acrolein level and myeloperoxidase gene polymorphism in COPD Source: Annual Congress 2010 - COPD: phenotyping and monitoring Year: 2010 Can plasma arginase levels differantiate asthma and COPD? Source: Eur Respir J 2007; 30: Suppl. 51, 372s Year: 2007 Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes Source: International Congress 2018 – Disease exacerbations from a molecular point of view Year: 2018 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018